Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Spiller, Susan E ^a,b   Logsdon, Naomi J ^a   Deckard, Lindsey A ^a   Sontheimer, Harald ^b,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR RELA; BORONIC ACID DERIVATIVE; BORTEZOMIB; CURCUMIN; DIETHYLDITHIOCARBAMIC ACID; I KAPPA B; I KAPPA B BETA; PYRAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE; PYRROLIDINE DITHIOCARBAMIC ACID; SALAZOSULFAPYRIDINE; THIOCARBAMIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MEDULLOBLASTOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CEREBELLUM TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENE; TUMOR CELL LINE;

ANIMALS; BORONIC ACIDS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; CURCUMIN; DITIOCARB; HUMANS; I-KAPPA B PROTEINS; MEDULLOBLASTOMA; MICE; MICE, INBRED C57BL; MICE, NUDE; NF-KAPPA B; PYRAZINES; PYRROLIDINES; SIGNAL TRANSDUCTION; SULFASALAZINE; THIOCARBAMATES; TRANSGENES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79953852369     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-136     Document Type: Article

References (55)

1. Packer R, Vezina G. Management of and prognosis with medulloblastoma. Arch Neurol 2008, 65:1419-1424. 10.1001/archneur.65.11.1419, 19001159.
2. Pollack IF. Infratentorial primitive neuroectodermal tumors. Tumors of the pediatric central nervous system 2001, 251-264. New York: Thieme Medical Publishers, Inc, Keating RF, Goodrich JT, Packer RJ.
3. Gilbertson RJ. Medulloblastoma: signaling a change in treatment. Lancet Oncol 2004, 5:209-218. 10.1016/S1470-2045(04)01424-X, 15050952.
4. Hatton BA, Villavicencio EH, Tsuchiya KD, Pritchard JI, Ditzler S, Pullar B, Hansen S, Knoblaugh SE, Lee D, Eberhart CG, Hallahan AR, Olson JM. The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res 2008, 68:1768-1776. 10.1158/0008-5472.CAN-07-5092, 18339857.
5. Nicolis SK. Cancer stem cells and "stemness" genes in neuro-oncology. Neurobiol Dis 2007, 25:217-229. 10.1016/j.nbd.2006.08.022, 17141509.
6. Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ 2006, 13:759-772. 10.1038/sj.cdd.4401838, 16410803.
7. Gilmore T, Gapuzan ME, Kalaitzidis D, Starczynowski D. Rel/NF-κB/IκB signal transduction in the generation and treatment of human cancer. Cancer Lett 2002, 181:1-9. 10.1016/S0304-3835(01)00795-9, 12430173.
8. Inoue J, Gohda J, Akiyama T, Semba K. NF-κB activation in development and progression of cancer. Cancer Sci 2007, 98:268-274. 10.1111/j.1349-7006.2007.00389.x, 17270016.
9. Rayet B, Gelinas C. Aberrant rel/nfκb genes and activity in human cancer. Oncogene 1999, 18:6938-6947. 10.1038/sj.onc.1203221, 10602468.
10. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2:301-310. 10.1038/nrc780, 12001991.
11. Hayden MS, Ghosh S. Shared Principles in NF-κB Signaling. Cell 2008, 132:344-362. 10.1016/j.cell.2008.01.020, 18267068.
12. Van Waes C. Nuclear factor-κB in development, prevention, and therapy of cancer. Clin Cancer Res 2007, 13:1076-1082. 10.1158/1078-0432.CCR-06-2221, 17317814.
13. Adamson DC, Shi Q, Wortham M, Northcott PA, Di C, Duncan CG, Li J, McLendon RE, Bigner DD, Taylor MD, Yan H. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res 2010, 70:181-191. 10.1158/0008-5472.CAN-09-2331, 2943736, 20028867.
14. Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, Lengauer C, Cummins JM, Velculescu VE, Fults DW, McLendon RE, Bigner DD, Yan H. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res 2005, 65:919-924.
15. Ness JM, Akhtar RS, Latham CB, Roth KA. Combined tyramide signal amplification and quantum dots for sensitive and photostable immunofluorescence detection. J Histochem Cytochem 2003, 51:981-987. 10.1177/002215540305100801, 12871979.
16. Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, Biswas DK. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther 2007, 6:1973-1982. 10.1158/1535-7163.MCT-07-0063, 17620428.
17. Raychaudhuri B, Han Y, Lu T, Vogelbaum MA. Aberrant constitutive activation of nuclear factor κB in glioblastoma multiforme drives invasive phenotype. J Neurooncol 2007, 85:39-47. 10.1007/s11060-007-9390-7, 17479228.
18. Smith D, Shimamura T, Barbera S, Bejcek BE. NF-κB controls growth of glioblastomas/astroctyomas. Mol Cell Biochem 2008, 307:141-147. 10.1007/s11010-007-9593-4, 17828582.
19. La Ferla-Brühl K, Westhoff MA, Karl S, Kasperczyk H, Zwacka RM, Debatin KM, Fulda S. NF-kappaB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition. Oncogene 2007, 26:571-582.
20. Chung WJ, Sontheimer H. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-κB. J Neurochem 2009, 110:182-93. 10.1111/j.1471-4159.2009.06129.x, 3031868, 19457125.
21. Meffert MD, Baltimore D. Physiological functions for brain NF-κB. Trends Neurosci 2005, 28:37-43. 10.1016/j.tins.2004.11.002, 15626495.
22. Kaltschmidt B, Widera D, Kaltschmidt C. Signaling via NF-κB in the nervous system. Biochmi Biophys ACTA 2005, 1745:287-299.
23. Yu Z, Zhou D, Bruce-Keller AJ, Kindy MS, Mattson MP. Lack of the p50 subunit of nuclear factor-κB increases the vulnerability of hippocampal neurons to excitotoxic injury. J Neurosci 1999, 19:8856-8865.
24. Mattson MP, Goodman Y, Luo H, Fu W, Furukawa K. Activation of NF-κB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. J Neurosci Res 1997, 49:681-697. 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3, 9335256.
25. Piccioli P, Porcile C, Stanzione S, Bisaglia M, Bajetto A, Bonavia R, Florio T, Schettini G. Inhibition of nuclear factor-κB activation induces apoptosis in cerebellar granule cells. J Neurosci Res 2001, 66:1064-1073. 10.1002/jnr.1251, 11746438.
26. Blondeau N, Widmann C, Lazdunski M, Heurteaux C. Activation of the nuclear factor-κB is a key event in brain tolerance. J Neurosci 2001, 21:4668-4677.
27. Guerrini L, Blasi F, Denis-Donini S. Synaptic activation of NF-κB by glutamate in cerebellar granule neurons in vitro. Proc Natl Acad Sci 1995, 92:9077-9081. 10.1073/pnas.92.20.9077, 40927, 7568076.
28. Kaltschmidt B, Kaltschmidt C. DNA array analysis of the developing rat cerebellum: transforming growth factor-κ2 inhibits constitutively activated NF-κB in granule neurons. Mech Dev 2001, 101:11-19. 10.1016/S0925-4773(00)00542-6, 11231055.
29. Widera D, Kaus A, Kaltschmidt C, Kaltschmidt B. Neural stem cells, inflammation and NF-κB: basic principle of maintenance and repair or origin of brain tumours?. J Cell Mol Med 2008, 12:459-470. 10.1111/j.1582-4934.2007.00208.x, 18182066.
30. Poulaki V, Mitsiades CS, Joussen AM, Lappas A, Kirchhof B, Mitsiades N. Constitutive nuclear factor-κB activity is crucial for human retinoblastoma cell viability. Am J Pathol 2002, 161:2229-2240. 10.1016/S0002-9440(10)64499-9, 1850903, 12466137.
31. Freudlsperger C, Greten J, Schumacher U. Curcumin induces apoptosis in human neuroblastoma cells via inhibition of NF-kappaB. Anticancer Res 2008, 28:209-214.
32. Armstrong MB, Schumacher KR, Mody R, Yanik GA, Opipari AW, Castle VP. Bortezomib as a therapeutic candidate for neuroblastoma. J Exp Ther Oncol 2008, 7:135-145.
33. Zenali MJ, Zhang PL, Bendel AE, Brown RE. Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in Ewing family of tumors. Ann Clin Lab Sci 2009, 39:160-166.
34. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A, Hall BM, Qualman SJ, Chandler DS, Croce CM, Guttridge DC. NF-κB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008, 14:369-381. 10.1016/j.ccr.2008.10.006, 18977326.
35. Kokkinakis DM, Liu X, Chada S, Ahmed MM, Shareef MM, Singha UK, Yang S, Luo J. Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress. Cancer Res 2004, 64:7513-7525. 10.1158/0008-5472.CAN-04-0592, 15492278.
36. Kumar AP, Garcia GE, Orsborn J, Levin VA, Slaga TJ. 2-Methoxyestradiol interferes with NFκB transcriptional activity in primitive neuroectodermal brain tumors: implications for management. Carcinogenesis 2003, 24:209-216. 10.1093/carcin/24.2.209, 12584169.
37. Bachmeier BE, Nerlich AG, Iancu CM, Cilli M, Schleicher E, Vene R, Dell'Eva R, Jochum M, Albini A, Pfeffer U. The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem 2007, 19:137-152. 10.1159/000099202, 17310108.
38. Divya CS, Pillai MR. Antitumor action of curcumin in human papilloavirus associated cells involves downregulation of viral oncogenes, prevention of NFκb and AP-1 translocation and modulation of apoptosis. Mol Carcinog 2006, 45:320-332. 10.1002/mc.20170, 16526022.
39. Hussain AR, Ahmed M, Al-Jomah NA, Khan AS, Manogaran P, Sultana M, Abubaker J, Platanias LC, Al-Kuraya KS, Uddin S. Curcumin suppresses constitutive activation of nuclear factor-κB and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 2008, 7:3318-3329. 10.1158/1535-7163.MCT-08-0541, 18852135.
40. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998, 101:1163-1174. 10.1172/JCI992, 508669, 9486988.
41. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NFκB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β. Gastroenterology 2000, 119:1209-1218. 10.1053/gast.2000.19458, 11054378.
42. Ahtoniemi T, Goldsteins G, Keksa-Goldsteine V, Malm T, Kanninen K, Salminen A, Koistinaho J. Pyrrolidine dithiocarbamate inhibits induction of immunoproteasome and decreases survival in a rat model of amyotrophic lateral sclerosis. Mol Pharmacol 2007, 71:30-37. 10.1124/mol.106.028415, 17008387.
43. Chen D, Peng F, Cui QC, Daniel KG, Orlu S, Liu J, Dou QP. Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. Front Biosci 2005, 10:2932-2939. 10.2741/1749, 15970547.
44. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor κB activation in intact cells. J Exp Med 1992, 175:1181-1194. 10.1084/jem.175.5.1181, 2119220, 1314883.
45. Chung KC, Park JH, Kim CH, Lee HW, Sato N, Uchiyama Y, Ahn YS. Novel biphasic effect of pyrrolidine dithiocarbamate on neuronal cell viability is mediated by the differential regulation of intracellular zinc and copper ion levels, NF-κB, and MAP kinases. J Neurosci Res 2000, 59:117-125. 10.1002/(SICI)1097-4547(20000101)59:1<117::AID-JNR14>3.0.CO;2-Q, 10658192.
46. Ernest NJ, Logsdon NJ, McFerrin MB, Sontheimer H, Spiller SE. Biophysical properties of human medulloblastoma cells. J Membrane Biol 2010, 237:59-69.
47. Cusack JC, Liu R, Baldwin AS. NF- kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF- kappa B. Drug Resist Updat 1999, 2:271-273. 10.1054/drup.1999.0094, 11504498.
48. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001, 107:135-142. 10.1172/JCI11914, 199180, 11160126.
49. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001, 107:241-246. 10.1172/JCI11991, 199203, 11160144.
50. Bian X, McAllister-Lucas LM, Shao F, Schumacher KR, Feng Z, Porter AG, Castle VP, Opipari AW. NF-κB activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem 2001, 276:48921-48929. 10.1074/jbc.M108674200, 11679590.
51. Armstrong MB, Bian X, Liu Y, Subramanian C, Ratanaproeksa AB, Shao F, Yu VC, Kwok RP, Opipari AW, Castle VP. Signaling from p53 to NF-kappa B determines the chemotherapy responsiveness of neuroblastoma. Neoplasia 2006, 8:964-974. 10.1593/neo.06574, 1764827, 17215959.
52. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999, 18:6853-6866. 10.1038/sj.onc.1203239, 10602461.
53. He HN, Wang X, Zheng XL, Sun H, Shi XW, Zhong YJ, Huang B, Yang L, Li JK, Liao LC, Zhang L, Hu LN, Lin Y. Concurrent blockade of the NF-κB and Akt pathways potently sensitizes cancer cells to chemotherapeutic-induced cytotoxicity. Cancer Lett 2010, 295:38-43. 10.1016/j.canlet.2010.02.011, 20207071.
54. Ding GR, Honda N, Nakahara T, et al. Radiosensitization by inhibition of IκB-α phosphorylation in human glioma cells. Radiat Res 2003, 160:232-237. 10.1667/RR3018, 12859235.
55. Yamagishi N, Miyakoshi J, Takebe H. Enhanced radiosensitivity by inhibition of nuclear factor κB activation in human malignant glioma cells. Int J Radiat Biol 1997, 72:157-162. 10.1080/095530097143374, 9269308.